Responses
Clinical/translational cancer immunotherapy
Original research
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Compose a Response to This Article
Other responses
No responses have been published for this article.
